KITE 718

Drug Profile

KITE 718

Alternative Names: KITE-718

Latest Information Update: 18 Mar 2017

Price : $50

At a glance

  • Originator Kite Pharma
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action MAGEA-3-protein-modulators; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Feb 2017 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Late stage disease, Recurrent, Second-line therapy or greater) in USA (IV) (Kite Pharma pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top